Cargando…
Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541727/ https://www.ncbi.nlm.nih.gov/pubmed/37786535 http://dx.doi.org/10.1177/17588359231201818 |
| _version_ | 1785113959480688640 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10541727 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105417272023-10-02 Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer Ther Adv Med Oncol Corrigendum SAGE Publications 2023-09-29 /pmc/articles/PMC10541727/ /pubmed/37786535 http://dx.doi.org/10.1177/17588359231201818 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Corrigendum Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer |
| title | Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer |
| title_full | Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer |
| title_fullStr | Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer |
| title_full_unstemmed | Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer |
| title_short | Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer |
| title_sort | corrigendum to rationale and trial design of natalee: a phase iii trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with hr+/her2− early breast cancer |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541727/ https://www.ncbi.nlm.nih.gov/pubmed/37786535 http://dx.doi.org/10.1177/17588359231201818 |